LGD-4033 (Ligandrol) – Solution, 300mg (10mg/mL)
$49.99
-
LGD-4033 (Ligandrol) – Solution, 300mg (10mg/mL) is ultra-pure, analytical-grade selective androgen receptor modulator (SARM) solution with ≥98% purity, designed for in vitro/in vivo metabolic research and analytical testing. This ready-to-use solution provides 10mg/mL concentration containing 300mg total LGD-4033 (30mL volume), functioning as a third-generation nonsteroidal oral SARM with strong affinity for the androgen receptor (Ki ≈ 1 nM), selectively binding to receptors in skeletal muscle, bone, and connective tissue with very little affinity for receptors in the prostate, scalp, and skin, making it invaluable for investigators studying muscle atrophy prevention, osteoporosis treatment, lean body mass preservation, bone mineral density enhancement, nitrogen retention, lipolysis stimulation, and tissue-selective AR signaling pathways developed by Ligand Pharmaceuticals without the virilizing consequences that come with anabolic steroids. Available for fast, compliant shipping to all U.S. states and European countries via dedicated logistics hubs.
-
Third-party certified lot coding with publicly available COA (Certificate of Analysis) for absolute purity transparency
-
Formulation completely free of flow agents, excipients, and adulterants to ensure 100% pure LGD-4033 solution
-
Precision over-filled by 5-10% inside vessel to compensate for natural solution adhesion loss during laboratory transfer
-
UV-resistant amber glass bottle with tamper-proof seal engineered for transit safety and chemical stability
-
LGD-4033 (Ligandrol) – Solution, 300mg (10mg/mL)
This premium, laboratory-grade research compound delivers ultra-pure LGD-4033 (Ligandrol) solution at 10mg/mL concentration, representing the highest standard for modern scientific investigations into selective androgen receptor modulation and anabolic signaling mechanisms in muscle and bone. The ready-to-use solution format eliminates preparation time and ensures precise dosing accuracy for in vivo animal studies, eliminating solubility variability and providing investigators with a validated vehicle system ideal for analytical testing, pharmacokinetic modeling, and in vivo preclinical research applications where precise LGD-4033 administration is critical for studying muscle atrophy prevention, bone density enhancement, and tissue-selective androgenic effects.
All shipments to the 50 United States are fulfilled directly from primary U.S. production facilities, ensuring 2-5 business day delivery nationwide. International orders to the United Kingdom and continental Europe are processed through our dedicated United Kingdom shipping hub, which streamlines customs clearance and reduces transit times across all European countries. This dual-hub logistics infrastructure guarantees seamless, compliant delivery while maintaining chemical integrity throughout transit.
-
Public third-party lab reports with unique lot-coding ensure absolute transparency for every batch sold
-
Formulation contains zero flow agents, excipients, or adulterants—pure LGD-4033 solution only
-
Strategic over-fill compensates for solution adhesion loss, guaranteeing minimum 30mL (300mg) recoverable volume
-
Amber glass bottle features UV-resistant construction and tamper-proof seal for transit safety
Technical Specifications & Chemical Profile
| Chemical Property | Specification Data |
|---|---|
| Product Name | LGD-4033 (Ligandrol) – Solution, 300mg (10mg/mL) |
| Common Synonyms | Ligandrol, VK-5211, LGD4033, LGD 4033, LGD-4, Anabolicum, Nonsteroidal SARM, LGD-4033 Liquid |
| CAS Number | 1165910-22-4 (free base) |
| Molecular Formula | C₁₄H₁₂F₆N₂O |
| Molar Mass | 338.25 g/mol |
| IUPAC Name | 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile |
| Primary Target Mechanism | Third-generation nonsteroidal oral selective androgen receptor modulator (SARM); strong affinity for androgen receptor (Ki ≈ 1 nM); tissue-selective binding to skeletal muscle, bone, and connective tissue; minimal affinity for prostate, scalp, and skin receptors; selective binding and activation of androgen receptor; promotes anabolic activity without significantly impacting androgenic organs; potential to prevent muscle wasting; promote muscle growth; enhance bone mineral density; addresses muscle atrophy and osteoporosis; without virilizing consequences of anabolic steroids; favorable pharmacokinetic profile; safe in clinical studies; half-life: 24-36 hours; increases lean body mass; increases nitrogen retention; lipolysis stimulation; bone density enhancement; lean mass preservation; orally bioavailable |
| Physical Form | Clear liquid solution (10mg/mL ±5%); 30mL total volume containing 300mg LGD-4033 |
Research Applications & Storage Protocols
SARM-Mediated AR Agonism & Muscle/Bone Enhancement Profiling
LGD-4033 (also known as VK-5211 and Ligandrol) functions as a novel, potent and selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals, being investigated for treatment of conditions such as muscle wasting and osteoporosis. The compound is a third-generation non-steroidal oral SARM that possesses a strong affinity for the androgen receptor, with a Ki of approximately 1 nM, making it an orally bioavailable selective androgen receptor modulator that binds to the androgen receptor with high affinity. Unlike testosterone, which produces anabolic effects via the same pathway, LGD-4033 selectively binds to receptors in skeletal muscle, bone, and connective tissue, with very little affinity for receptors in the prostate, scalp, and skin, demonstrating tissue-selective activation of androgenic signaling. LGD-4033 has been reported to dose-dependently improve lean body mass and muscle strength in preliminary clinical trials, and SARMs selectively bind to androgen receptors in specific tissues like muscle and bone, rather than the prostate or other androgen-sensitive organs, raising the possibility that they might increase muscle mass but avoid some of the negative effects of testosterone and other androgens. It has been studied as a treatment for muscle wasting in people with muscular dystrophy or osteoporosis, or those getting treated for cancer, because of its ability to increase muscle mass. Results of the first human clinical trial of LGD-4033 were published in 2013 and found that it increased lean body mass without serious adverse side effects in the short term, and LGD-4033 was safe, had a favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen, demonstrating its selective anabolic profile. LGD-4033 increases lean body mass, increases nitrogen retention, and stimulates lipolysis (fat breakdown), demonstrating comprehensive anabolic effects for muscle health. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects, offering additional therapeutic potential beyond muscle and bone enhancement. This SARM mechanism positions LGD-4033 solution as a critical tool compound for investigating muscle atrophy prevention research, osteoporosis treatment models, lean body mass preservation studies, bone mineral density enhancement pathways, nitrogen retention mechanisms, lipolysis stimulation, and tissue-selective androgen receptor signaling in preclinical models, offering potential therapeutic insights for metabolic and musculoskeletal disorders.
Handling & Storage Guidelines
-
Long-Term Storage: Store at -20°C (-4°F) in a sealed container, away from light and moisture to maintain potency and maximize shelf life (up to 2 years). UV-resistant glass bottle minimizes degradation; tamper-proof seal ensures secure delivery. Avoid excessive heat and moisture; do not recommend long-term storage for solutions—use promptly after opening
-
Solubility: Pre-dissolved formulation ready for direct use; May dissolve in DMSO (in most cases); if not soluble in DMSO, try other solvents such as H₂O, Ethanol, or DMF with a minute amount of products to avoid loss of samples; water solubility low; for in vivo studies: appropriate vehicle formulation recommended; shake/agitate bottle before each administration for consistency
-
Appearance: Clear colorless to pale yellow liquid solution; 30mL volume containing 300mg total LGD-4033 at 10mg/mL concentration; <5% concentration variance for consistency
Global Logistics & Order Fulfillment
We proudly support scientific advancement across all 50 U.S. states and throughout Europe. Customers can seamlessly toggle their preferred currency between USD and EUR using the currency switcher located on the left-hand side of our website. All shipments are securely packaged to withstand international transit without compromising structural or chemical stability.
Laboratory Use Only Disclaimer
This material is sold strictly for laboratory research and development use only. It is not approved for human consumption, nor for medical, veterinary, or household applications. All purchases are governed by our standard Terms & Conditions. Please review them carefully before placing your order.
| pa_feature |
Discountinued |
|---|---|
| pa_form |
Liquids |
| pa_types |
SARMs |
You must be logged in to post a review.


Reviews
There are no reviews yet.